• 1
    Bouvier, N. M. and Palese, P., The biology of influenza viruses. Vaccine 2008. 26(S4): D49D53.
  • 2
    Carrat, F. and Flahault, A., Influenza vaccine: the challenge of antigenic drift. Vaccine 2007. 25: 68526862.
  • 3
    Schwartz, B. and Wortley, P., Mass vaccination for annual and pandemic influenza. Curr. Top Microbiol. Immunol. 2006. 304: 131152.
  • 4
    Effros, R. B., Doherty, P. C., Gerhard, W. and Bennink, J., Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J. Exp. Med. 1977. 145: 557568.
  • 5
    Thomas, P. G., Keating, R., Hulse-Post, D. J. and Doherty, P. C., Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 2006. 12: 4854.
  • 6
    Zweerink, H. J., Askonas, B. A., Millican, D., Courtneidge, S. A. and Skehel, J. J., Cytotoxic T cells to type A influenza virus; viral hemagglutinin induces A-strain specificity while infected cells confer cross-reactive cytotoxicity. Eur. J. Immunol. 1977. 7: 630635.
  • 7
    Gotch, F., McMichael, A., Smith, G. and Moss, B., Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 1987. 165: 408416.
  • 8
    Townsend, A. R. and Skehel, J. J., The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J. Exp. Med. 1984. 160: 552563.
  • 9
    Epstein, S. L., Kong, W. P., Misplon, J. A., Lo, C. Y., Tumpey, T. M., Xu, L. and Nabel, G. J., Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005. 23: 54045410.
  • 10
    Lee, L. Y., Ha do, L. A., Simmons, C., de Jong, M. D., Chau, N. V., Schumacher, R., Peng, Y. C. et al., Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 2008. 118: 34783490.
  • 11
    Liang, S., Mozdzanowska, K., Palladino, G. and Gerhard, W., Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 1994. 152: 16531661.
  • 12
    McMichael, A. J., Gotch, F. M., Dongworth, D. W., Clark, A. and Potter, C. W., Declining T-cell immunity to influenza, 1977–82. Lancet 1983. 2: 762764.
  • 13
    Ito, T., Gorman, O. T., Kawaoka, Y., Bean, W. J. and Webster, R. G., Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 1991. 65: 54915498.
  • 14
    Zebedee, S. L. and Lamb, R. A., Nucleotide sequences of influenza A virus RNAsegment 7: a comparison of five isolates. Nucleic Acids Res. 1989. 17: 2870.
  • 15
    De Filette, M., Martens, W., Smet, A., Schotsaert, M., Birkett, A., Londono-Arcila, P., Fiers, W. and Saelens, X., Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008. 26: 65036507.
  • 16
    Huleatt, J. W., Nakaar, V., Desai, P., Huang, Y., Hewitt, D., Jacobs, A., Tang, J. et al., Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008. 26: 201214.
  • 17
    Jegerlehner, A., Schmitz, N., Storni, T. and Bachmann, M. F., Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004. 172: 55985605.
  • 18
    Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M. and Fiers, W., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999. 5: 11571163.
  • 19
    Okuda, K., Ihata, A., Watabe, S., Okada, E., Yamakawa, T., Hamajima, K., Yang, J. et al., Protective immunity against influenza A virus induced by immunization with DNAplasmid containing influenza M gene. Vaccine 2001. 19: 36813691.
  • 20
    Slepushkin, V. A., Katz, J. M., Black, R. A., Gamble, W. C., Rota, P. A. and Cox, N. J., Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995. 13: 13991402.
  • 21
    Fan, J., Liang, X., Horton, M. S., Perry, H. C., Citron, M. P., Heidecker, G. J., Fu, T. M. et al., Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004. 22: 29933003.
  • 22
    Fu, T. M., Grimm, K. M., Citron, M. P., Freed, D. C., Fan, J., Keller, P. M., Shiver, J. W. et al., Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009. 27: 14401447.
  • 23
    Zebedee, S. L. and Lamb, R. A., Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 1988. 62: 27622772.
  • 24
    Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J. and Metzger, D. W., Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001. 166: 73817388.
  • 25
    El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N. et al., Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011. 186: 10221031.
  • 26
    Beerli, R. R., Bauer, M., Buser, R. B., Gwerder, M., Muntwiler, S., Maurer, P., Saudan, P. and Bachmann, M. F., Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl. Acad. Sci. U S A 2008. 105: 1433614341.
  • 27
    Beerli, R. R., Bauer, M., Schmitz, N., Buser, R. B., Gwerder, M., Muntwiler, S., Renner, W. A. et al., Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol. J. 2009. 6: 224235.
  • 28
    Armour, K. L., Clark, M. R., Hadley, A. G. and Williamson, L. M., Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 1999. 29: 26132624.
  • 29
    Nimmerjahn, F. and Ravetch, J. V., Fc-receptors as regulators of immunity. Adv. Immunol. 2007. 96: 179204.
  • 30
    Fu, T. M., Freed, D. C., Horton, M. S., Fan, J., Citron, M. P., Joyce, J. G., Garsky, V. M. et al., Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 2009. 385: 218226.
  • 31
    Tissot, A. C., Renhofa, R., Schmitz, N., Cielens, I., Meijerink, E., Ose, V., Jennings, G. T. et al., Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010. 5: e9809.
  • 32
    Bessa, J., Kopf, M. and Bachmann, M. F., Cutting edge: IL-21 and TLRsignaling regulate germinal center responses in a B cell-intrinsic manner. J. Immunol. 2010. 184: 46154619.
  • 33
    Jegerlehner, A., Maurer, P., Bessa, J., Hinton, H. J., Kopf, M. and Bachmann, M. F., TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 2007. 178: 24152420.
  • 34
    Hou, B., Saudan, P., Ott, G., Wheeler, M. L., Ji, M., Kuzmich, L., Lee, L. M. et al., Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 2011. 34: 375384.
  • 35
    Koyama, S., Aoshi, T., Tanimoto, T., Kumagai, Y., Kobiyama, K., Tougan, T., Sakurai, K. et al., Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci. Transl. Med. 2010. 2: 25ra24.
  • 36
    Geeraedts, F., Goutagny, N., Hornung, V., Severa, M., de Haan, A., Pool, J., Wilschut, J. et al., Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008. 4: e1000138.
  • 37
    Bessa, J., Jegerlehner, A., Hinton, H. J., Pumpens, P., Saudan, P., Schneider, P. and Bachmann, M. F., Alveolar macrophages and lung dendritic cells sense RNAand drive mucosal IgA responses. J. Immunol. 2009. 183: 37883799.
  • 38
    Keller, S. A., Schwarz, K., Manolova, V., von Allmen, C. E., Kinzler, M. G., Bauer, M., Muntwiler, S., et al., Innate signaling regulates cross-priming at the level of DClicensing and not antigen presentation. Eur. J. Immunol. 2009. 40: 103112.